How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Ex-Meta and DeepMind researchers raised $650m at a $4.65bn valuation for Recursive Superintelligence, a startup betting AI can automate its own research.
UIUC and Stanford's RecursiveMAS lets AI agents collaborate in embedding space instead of text, cutting token usage by 75% ...
Richard Socher's new $650 million startup wants to build an AI that can research and improve itself indefinitely — and he ...
The science of learning is an interdisciplinary area of study that investigates the processes of human learning. It builds on a long history of research from developmental psychology, linguistics, ...
A new frontier AI company called Recursive Superintelligence has emerged from stealth with $650 million in funding and an unusually ambitious goal: building AI systems capable of improving themselves ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results